psalexa
logo

Rectal Cancer Therapeutics - Pipeline Analysis 2018

Rectal Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: March 2018
Report Code: LS11420
Available Format:
Pages: 100

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Rectal cancer is a disease in which malignant (cancer) cells are formed in the tissues of the rectum. Rectal cancer usually develops over several years, first growing as a precancerous growth known as polyp. Some polyps can turn into cancer and begin to grow by its different stages. The actual cause of rectal cancer is unclear and some of risk factors that can cause rectal cancer are aging, smoking, family history of colon or rectal cancer, inflammatory bowel disease, and high fat diet or diet mostly from animal sources.

 

RECTAL CANCER DRUG CANDIDATES UNDER DEVELOPMENT (2018)

RECTAL-CANCER-DRUG-CANDIDATES-UNDER-DEVELOPMENT

Most of the drug candidates for the treatment of rectal cancer are being developed as small molecule which are obtained from synthetic sources, which is mostly cost-effective and easy to manufacture and perform quantitative and qualitative testing. The factors supporting growth of rectal cancer therapeutics pipeline include, increasing focus towards the development of targeted therapies and rising geriatric population.

Pipeline Analysis

After thorough study, it has been observed that most of the drug candidates for treatment of rectal cancer are in the clinical stage of development. This is expected to lead to more certainty of drug approvals for the treatment of rectal cancer, with positive clinical results, in coming years. As of March 2018, the rectal cancer therapeutics pipeline comprises of 15 drug candidates in different stages of development.

Competitive Landscape

Some of the key players involved in the development of rectal cancer therapeutics include Taiwan Liposome Company, Sanofi and Advaxis Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry